Could ARGOS THERAPEUTICS INC (OTCMKTS:ARGS) Skyrocket? The Stock Had Too Little Sellers

June 18, 2018 - By Maria Brooks

Argos Therapeutics, Inc. (OTCMKTS:ARGS) Logo

The stock of ARGOS THERAPEUTICS INC (OTCMKTS:ARGS) registered a decrease of 91.01% in short interest. ARGS’s total short interest was 65,500 shares in June as published by FINRA. Its down 91.01% from 728,400 shares, reported previously.

The stock decreased 5.50% or $0.0099 during the last trading session, reaching $0.1701. About 16,951 shares traded. Argos Therapeutics, Inc. (OTCMKTS:ARGS) has 0.00% since June 18, 2017 and is . It has underperformed by 12.57% the S&P500.

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company has market cap of $1.80 million. The firm develops immunotherapies based on its proprietary technology platform, Arcelis. It currently has negative earnings. The Company’s product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: